MINDY2

Across TCGA pan-cancer cohorts, MINDY2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MINDY2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MINDY2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MINDY2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where MINDY2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.349	0.609	.005	30	view →
GBM	DFS	Median	All	0.880	0.620	<.001	18	view →
HNSC	DFS	Tertile	II,III,IV	0.824	0.605	.027	3	view →
LSCC	DFS	Median	II,III,IV	0.693	0.852	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MINDY2–PDAC (DFS)

Open the PDAC breakdown →